Catalyst Pharmaceuticals, Inc.
CPRX
Classificação em ações
#4171
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Preço da ação
$31.49
Última sincronização: 2026-07-21
Valor de mercado
$3.85B
Variação (1 dia)
0.00%
Variação (1 ano)
49.88%
País
US
Negociar Catalyst Pharmaceuticals, Inc. (CPRX)
Categoria
Healthcare
Rácio P/S de Catalyst Pharmaceuticals, Inc. (CPRX)
Rácio P/S em October 2026 TTM: 6.46
De acordo com os relatórios financeiros mais recentes e o preço das ações da Catalyst Pharmaceuticals, Inc., o rácio P/S atual (TTM) é 6.46. No final de 2023, o rácio P/S era 4.49.
Histórico do rácio P/S da Catalyst Pharmaceuticals, Inc. de 2002 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 6.46 | 28.38% |
| 2024 | 5.03 | 12.06% |
| 2023 | 4.49 | -50.02% |
| 2022 | 8.98 | 80.63% |
| 2021 | 4.97 | 71.16% |
| 2020 | 2.90 | -23.05% |
| 2019 | 3.77 | -99.04% |
| 2018 | 394.11 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | 37.62 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | 55.20% |
US
|
|
| 40.55 | 527.95% |
US
|
|
| 3.96 | -38.66% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 57.12% |
NL
|
